View in EDS

Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.

Saved in:
Bibliographic Details
Title: Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Authors: Scribner JA; MacroGenics, Inc., Brisbane, CA., Hicks SW; ImmunoGen, Inc., Waltham, MA., Sinkevicius KW; ImmunoGen, Inc., Waltham, MA., Yoder NC; ImmunoGen, Inc., Waltham, MA., Diedrich G; MacroGenics, Inc., Rockville, MD., Brown JG; MacroGenics, Inc., Rockville, MD., Lucas J; ImmunoGen, Inc., Waltham, MA., Fuller ME; ImmunoGen, Inc., Waltham, MA., Son T; MacroGenics, Inc., Brisbane, CA., Dastur A; ImmunoGen, Inc., Waltham, MA., Hooley J; MacroGenics, Inc., Brisbane, CA., Espelin C; ImmunoGen, Inc., Waltham, MA., Themeles M; ImmunoGen, Inc., Waltham, MA., Chen FZ; MacroGenics, Inc., Brisbane, CA., Li Y; MacroGenics, Inc., Brisbane, CA., Chiechi M; MacroGenics, Inc., Brisbane, CA., Lee J; ImmunoGen, Inc., Waltham, MA., Barat B; MacroGenics, Inc., Rockville, MD., Widjaja L; MacroGenics, Inc., Rockville, MD., Gorlatov S; MacroGenics, Inc., Rockville, MD., Tamura J; MacroGenics, Inc., Rockville, MD., Ciccarone V; MacroGenics, Inc., Rockville, MD., Ab O; ImmunoGen, Inc., Waltham, MA., McEachem KA; ImmunoGen, Inc., Waltham, MA., Koenig S; MacroGenics, Inc., Rockville, MD., Westin EH; MacroGenics, Inc., Rockville, MD., Moore PA; MacroGenics, Inc., Rockville, MD., Chittenden T; ImmunoGen, Inc., Waltham, MA., Gregory RJ; ImmunoGen, Inc., Waltham, MA., Bonvini E; MacroGenics, Inc., Rockville, MD., Loo D; MacroGenics, Inc., Brisbane, CA.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jul 05; Vol. 21 (7), pp. 1047-1059.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35511740
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Scribner+JA%22">Scribner JA</searchLink>; MacroGenics, Inc., Brisbane, CA.<br /><searchLink fieldCode="AU" term="%22Hicks+SW%22">Hicks SW</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Sinkevicius+KW%22">Sinkevicius KW</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Yoder+NC%22">Yoder NC</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Diedrich+G%22">Diedrich G</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Brown+JG%22">Brown JG</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Lucas+J%22">Lucas J</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Fuller+ME%22">Fuller ME</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Son+T%22">Son T</searchLink>; MacroGenics, Inc., Brisbane, CA.<br /><searchLink fieldCode="AU" term="%22Dastur+A%22">Dastur A</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Hooley+J%22">Hooley J</searchLink>; MacroGenics, Inc., Brisbane, CA.<br /><searchLink fieldCode="AU" term="%22Espelin+C%22">Espelin C</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Themeles+M%22">Themeles M</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Chen+FZ%22">Chen FZ</searchLink>; MacroGenics, Inc., Brisbane, CA.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; MacroGenics, Inc., Brisbane, CA.<br /><searchLink fieldCode="AU" term="%22Chiechi+M%22">Chiechi M</searchLink>; MacroGenics, Inc., Brisbane, CA.<br /><searchLink fieldCode="AU" term="%22Lee+J%22">Lee J</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Barat+B%22">Barat B</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Widjaja+L%22">Widjaja L</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Gorlatov+S%22">Gorlatov S</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Tamura+J%22">Tamura J</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Ciccarone+V%22">Ciccarone V</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Ab+O%22">Ab O</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22McEachem+KA%22">McEachem KA</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Koenig+S%22">Koenig S</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Westin+EH%22">Westin EH</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Moore+PA%22">Moore PA</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Chittenden+T%22">Chittenden T</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Gregory+RJ%22">Gregory RJ</searchLink>; ImmunoGen, Inc., Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Bonvini+E%22">Bonvini E</searchLink>; MacroGenics, Inc., Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Loo+D%22">Loo D</searchLink>; MacroGenics, Inc., Brisbane, CA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2022 Jul 05; Vol. 21 (7), pp. 1047-1059.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35511740
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-21-0915
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1047
    Titles:
      – TitleFull: Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Scribner JA
      – PersonEntity:
          Name:
            NameFull: Hicks SW
      – PersonEntity:
          Name:
            NameFull: Sinkevicius KW
      – PersonEntity:
          Name:
            NameFull: Yoder NC
      – PersonEntity:
          Name:
            NameFull: Diedrich G
      – PersonEntity:
          Name:
            NameFull: Brown JG
      – PersonEntity:
          Name:
            NameFull: Lucas J
      – PersonEntity:
          Name:
            NameFull: Fuller ME
      – PersonEntity:
          Name:
            NameFull: Son T
      – PersonEntity:
          Name:
            NameFull: Dastur A
      – PersonEntity:
          Name:
            NameFull: Hooley J
      – PersonEntity:
          Name:
            NameFull: Espelin C
      – PersonEntity:
          Name:
            NameFull: Themeles M
      – PersonEntity:
          Name:
            NameFull: Chen FZ
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Chiechi M
      – PersonEntity:
          Name:
            NameFull: Lee J
      – PersonEntity:
          Name:
            NameFull: Barat B
      – PersonEntity:
          Name:
            NameFull: Widjaja L
      – PersonEntity:
          Name:
            NameFull: Gorlatov S
      – PersonEntity:
          Name:
            NameFull: Tamura J
      – PersonEntity:
          Name:
            NameFull: Ciccarone V
      – PersonEntity:
          Name:
            NameFull: Ab O
      – PersonEntity:
          Name:
            NameFull: McEachem KA
      – PersonEntity:
          Name:
            NameFull: Koenig S
      – PersonEntity:
          Name:
            NameFull: Westin EH
      – PersonEntity:
          Name:
            NameFull: Moore PA
      – PersonEntity:
          Name:
            NameFull: Chittenden T
      – PersonEntity:
          Name:
            NameFull: Gregory RJ
      – PersonEntity:
          Name:
            NameFull: Bonvini E
      – PersonEntity:
          Name:
            NameFull: Loo D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 07
              Text: 2022 Jul 05
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1